Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FULC NASDAQ:GLPG NASDAQ:HRMY NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$7.11+1.3%$7.75$4.78▼$15.74$473.07M3.02968,662 shs243,439 shsGLPGGalapagos$28.82+1.5%$30.70$24.74▼$37.78$1.90B0.25141,173 shs49,912 shsHRMYHarmony Biosciences$32.37+0.1%$28.83$25.52▼$40.87$1.87B0.97861,457 shs391,763 shsVCELVericel$36.47-0.9%$34.02$28.95▼$45.97$1.86B1.15576,396 shs261,869 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics-4.68%-5.65%-12.69%-29.09%+22.51%GLPGGalapagos+1.39%-0.11%-3.50%-18.02%+4.57%HRMYHarmony Biosciences+1.60%+3.79%+16.58%-13.34%+7.94%VCELVericel+3.49%+3.25%+7.82%-0.19%-6.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$7.11+1.3%$7.75$4.78▼$15.74$473.07M3.02968,662 shs243,439 shsGLPGGalapagos$28.82+1.5%$30.70$24.74▼$37.78$1.90B0.25141,173 shs49,912 shsHRMYHarmony Biosciences$32.37+0.1%$28.83$25.52▼$40.87$1.87B0.97861,457 shs391,763 shsVCELVericel$36.47-0.9%$34.02$28.95▼$45.97$1.86B1.15576,396 shs261,869 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics-4.68%-5.65%-12.69%-29.09%+22.51%GLPGGalapagos+1.39%-0.11%-3.50%-18.02%+4.57%HRMYHarmony Biosciences+1.60%+3.79%+16.58%-13.34%+7.94%VCELVericel+3.49%+3.25%+7.82%-0.19%-6.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFULCFulcrum Therapeutics 2.50Moderate Buy$19.00167.23% UpsideGLPGGalapagos 2.14Hold$36.5026.67% UpsideHRMYHarmony Biosciences 2.42Hold$42.6731.81% UpsideVCELVericel 2.63Moderate Buy$55.4051.93% UpsideCurrent Analyst Ratings BreakdownLatest FULC, VCEL, GLPG, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026HRMYHarmony Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026HRMYHarmony Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/21/2026FULCFulcrum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026VCELVericel Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$48.00 ➝ $42.003/26/2026HRMYHarmony Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/10/2026VCELVericel Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$46.002/27/2026VCELVericel HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $64.002/26/2026GLPGGalapagos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C)2/25/2026HRMYHarmony Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/25/2026HRMYHarmony Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$46.00 ➝ $36.002/25/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFULCFulcrum Therapeutics$80M5.92N/AN/A$5.00 per share1.42GLPGGalapagos$1.26B1.51$0.74 per share39.20$47.57 per share0.61HRMYHarmony Biosciences$868.45M2.16$3.16 per share10.25$15.11 per share2.14VCELVericel$276.26M6.72$0.56 per share65.69$7.01 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%N/AGLPGGalapagos$363.05M-$1.57N/AN/AN/AN/AN/AN/A5/6/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.7111.928.540.4418.29%19.86%13.69%5/7/2026 (Confirmed)VCELVericel$16.52M$0.31117.6347.36N/A5.98%5.17%3.67%5/7/2026 (Estimated)Latest FULC, VCEL, GLPG, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026HRMYHarmony Biosciences$0.76N/AN/AN/A$220.84 millionN/A5/7/2026Q1 2026VCELVericel-$0.15N/AN/AN/A$63.68 millionN/A5/6/2026Q1 2026GLPGGalapagos-$1.1356N/AN/AN/A$39.65 millionN/A4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/A2/26/2026Q4 2025VCELVericel$0.45$0.45N/A$0.45$92.66 million$92.92 million2/24/2026Q4 2025FULCFulcrum Therapeutics-$0.31-$0.31N/A-$0.31N/AN/A2/24/2026Q4 2025HRMYHarmony Biosciences$0.84$0.38-$0.46$0.38$240.04 million$243.78 million2/15/2026Q4 2025GLPGGalapagosN/A$13.92N/A$13.92N/A$1.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFULCFulcrum TherapeuticsN/A34.3334.33GLPGGalapagosN/A20.1520.00HRMYHarmony Biosciences0.173.603.58VCELVericelN/A5.034.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFULCFulcrum Therapeutics89.83%GLPGGalapagos32.46%HRMYHarmony Biosciences86.23%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipFULCFulcrum Therapeutics7.00%GLPGGalapagos2.91%HRMYHarmony Biosciences11.00%VCELVericel7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFULCFulcrum Therapeutics10066.63 million61.97 millionOptionableGLPGGalapagos1,31065.90 million63.98 millionOptionableHRMYHarmony Biosciences20057.87 million51.50 millionOptionableVCELVericel30050.93 million47.06 millionOptionableFULC, VCEL, GLPG, and HRMY HeadlinesRecent News About These CompaniesWall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a BetMay 4 at 10:56 AM | zacks.comVericel Corporation (NASDAQ:VCEL) Receives $55.40 Average PT from AnalystsMay 3 at 4:47 AM | americanbankingnews.comVericel Shareholders Reaffirm Board, Pay Plan, AuditorMay 1, 2026 | tipranks.comConestoga Capital Advisors LLC Acquires 79,278 Shares of Vericel Corporation $VCELMay 1, 2026 | marketbeat.comVericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC AuditorMay 1, 2026 | marketbeat.comVericel (VCEL) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 28, 2026 | marketbeat.comVericel to Report First-Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | globenewswire.comVericel (NASDAQ:VCEL) Shares Down 7.1% - Time to Sell?April 21, 2026 | marketbeat.comInsider Selling: Vericel (NASDAQ:VCEL) Insider Sells 3,472 Shares of StockApril 7, 2026 | insidertrades.comJonathan Mark Hopper Sells 3,472 Shares of Vericel (NASDAQ:VCEL) StockApril 6, 2026 | marketbeat.comAberdeen Group plc Has $21.03 Million Stock Position in Vericel Corporation $VCELApril 6, 2026 | marketbeat.comVericel Gets $197M U.S. Government Contract for Burn TreatmentApril 2, 2026 | marketwatch.comMediWound and Vericel Secure Up to $197 Million BARDA Contract for NexoBrid® Procurement and DevelopmentApril 2, 2026 | quiverquant.comQVericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBridApril 2, 2026 | markets.businessinsider.comVericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBridApril 2, 2026 | globenewswire.comWhat Makes Vericel Corporation (VCEL) an Investment Bet?March 13, 2026 | insidermonkey.comWhat Makes Vericel Corporation (VCEL) an Investment Bet?March 13, 2026 | finance.yahoo.comWill FDA Approval of Burlington MACI Manufacturing Shift Vericel's (VCEL) Long-Term Growth NarrativeMarch 10, 2026 | finance.yahoo.comVericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACIMarch 10, 2026 | msn.comVericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing FacilityMarch 4, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFULC, VCEL, GLPG, and HRMY Company DescriptionsFulcrum Therapeutics NASDAQ:FULC$7.11 +0.09 (+1.28%) As of 02:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Galapagos NASDAQ:GLPG$28.82 +0.43 (+1.50%) As of 02:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Harmony Biosciences NASDAQ:HRMY$32.37 +0.03 (+0.09%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Vericel NASDAQ:VCEL$36.47 -0.35 (-0.94%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
